Table of Contents
ISRN Transplantation
Volume 2013, Article ID 281285, 5 pages
http://dx.doi.org/10.5402/2013/281285
Clinical Study

Tacrolimus Dose Modification in Hematopoietic Cell Transplant Recipients Following a Change in Therapy from Fluconazole to Voriconazole

1College of Pharmacy, The University of Tennessee, Knoxville Campus, 1924 Alcoa Highway, P.O. Box 117, Knoxville, TN 37920, USA
2Department of Clinical Pharmacy, School of Pharmacy and Section of Infectious Diseases, School of Medicine, West Virginia University, Morgantown, WV 26506, USA
3Department of Pharmacy and Mary Babb Randolph Cancer Center, West Virginia University Healthcare, Morgantown, WV 26506, USA

Received 13 August 2012; Accepted 30 August 2012

Academic Editors: R. De la Camara, H.-J. Kim, and R. Rezzani

Copyright © 2013 Anthony J. Guarascio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. G. Freifeld, E. J. Bow, K. A. Sepkowitz et al., “Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 52, no. 4, pp. e56–e93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. Prograf (Tacrolimus) Package Insert, Astellas Pharm US, Deerfield, Ill, USA, 2006.
  3. H. Kawazoe, T. Yoshiharu, T. Hiroaki et al., “Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation,” Biological and Pharmaceutical Bulletin, vol. 29, no. 12, pp. 2528–2531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Trifilio, M. H. Scheetz, J. Pi, and J. Mehta, “Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: Preemptive dose modification and therapeutic drug monitoring,” Bone Marrow Transplantation, vol. 45, no. 8, pp. 1352–1356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Mori, Y. Aisa, J. Kato, Y. Nakamura, Y. Ikeda, and S. Okamoto, “Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients,” Bone Marrow Transplantation, vol. 44, no. 6, pp. 371–374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Mihara, M. Takehiko, A. Yoshinobu et al., “Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole,” European Journal of Clinical Pharmacology, vol. 64, no. 1, pp. 89–91, 2008. View at Publisher · View at Google Scholar · View at Scopus